HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it intends to offer to sell, subject to market and other conditions, 2,667,000 shares of its common stock in an underwritten public offering. In addition to the shares being offered by the Company, 83,000 shares will be offered by a selling stockholder. The Company will grant the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock at the public offering price. The final terms of the offering will be disclosed in the final prospectus to be filed with the Securities and Exchange Commission.
